- Design of a dual sensing highly selective cyanide chemodosimeter based on pyridinium ring chemistry
-
A new chemodosimeter, Quino-P, recognizes the strongly nucleophilic cyanide by dual colorimetric and fluorescence 'off-on' signalling responses. Noteworthily, several other anions, even in significantly higher concentrations, induce no detectable photophysical perturbations. The chemodosimeter mechanism involves formation of a C4-cyano adduct, which exhibits an uncommon phenomenon of enhanced internal charge transfer interaction. The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2011.
- Mashraqui, Sabir H.,Betkar, Rupesh,Chandiramani, Mukesh,Estarellas, Carolina,Frontera, Antonio
-
-
Read Online
- Quinoline-4-carboxamide skeleton derivative and application thereof
-
The invention discloses a quinoline-4-formamide skeleton derivative and application thereof, belonging to the field of chemical medicines. The invention provides a compound as shown in a formula I or pharmaceutically acceptable salt thereof. The invention
- -
-
Paragraph 0048-0051; 0095-0098
(2021/06/09)
-
- Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity
-
SIRT6 activation is thought to be a promising target for the treatment of many diseases, particularly cancer. Herein, we report the discovery of a series of new small-molecule SIRT6 activators. Structure-activity relationship analyses led to the identific
- Chen, Xiuli,Sun, Weining,Huang, Shenzhen,Zhang, Hailin,Lin, Guifeng,Li, Hui,Qiao, Jingxin,Li, Linli,Yang, Shengyong
-
p. 10474 - 10495
(2020/11/02)
-
- NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087
-
The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.
- -
-
Page/Page column 223
(2009/07/25)
-
- Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues
-
CYP2C9 is a significant P450 protein responsible for drug metabolism. With the increased use of heterocyclic compounds in drug design, a rapid and efficient predrug screening of these potential type II binding compounds is essential to avoid adverse drug
- Peng, Chi-Chi,Cape, Jonathan L.,Rushmore, Tom,Crouch, Gregory J.,Jones, Jeffrey P.
-
experimental part
p. 8000 - 8011
(2009/12/07)
-
